The Quantellect read.As of Nov 19, 2026, 12 active firms cover Dentsply Sirona Inc: 3 rate it Buy or better, 7 sit at Neutral, and 2 rate it Sell or worse, a neutral consensus. Targets span $10.00 to $17.00, a moderate spread. The average target of $13.33 sits 56% above the current $8.53. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.26 next quarter toward $1.22 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 active firms
Neutral
Strong Buy00%
Buy325%
Neutral758%
Sell217%
Strong Sell00%
Based on 12 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$13.33
+56.4% upside
Average target across 12 active firms as of Nov 19, 2026 vs $8.53 current
Highest Target$17.00
Average Target$13.33
Lowest Target$10.00
Detailed analyst forecasts for XRAY
Showing 1–10 of 10 named analysts shown · 12 active firms in the rating projection
As of Nov 19, 2026, 3 of 12 active firms rate XRAY a Buy (7 Neutral, 2 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
XRAY EPS & revenue forecast
EPS · NEXT QUARTER
$0.26
Range $0.23 – $0.30 · 11 analysts · -3% YoY
Next period, 11 analysts expect Dentsply Sirona Inc to earn $0.26 a share (range $0.23 – $0.30), versus $0.27 a year earlier. Full-year consensus is $1.32, growing to $1.22 the year after.
REVENUE · NEXT QUARTER
$856.7M
Range $832.0M – $877.3M · 11 analysts · -3% YoY
Revenue is expected to reach $856.7M (range $832.0M – $877.3M), -2.7% year-over-year. Full-year consensus is $3.5B, rising to $3.5B next year.
Top analysts covering Dentsply Sirona Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on XRAY.
#1
Erin Wright
Morgan Stanley · Rank #81
Neutral
No targeton XRAY
Overall win rate
55%
+ Follow
#2
Kevin Caliendo
UBS · Rank #165
Buy
$17.00+99.4% to target
Overall win rate
42%
+ Follow
#3
Jonathan Block
Stifel · Rank #294
Neutral
$14.00+64.2% to target
Overall win rate
36%
+ Follow
#4
Jason Bednar
Piper Sandler · Rank #360
Neutral
$12.00+40.8% to target
Overall win rate
33%
+ Follow
#5
David Saxon
Needham · Rank #426
Neutral
No targeton XRAY
Overall win rate
32%
+ Follow
XRAY stock forecast FAQ
What is XRAY's average 12-month price target?+
The 12 active firms with a live target average $13.33 for Dentsply Sirona Inc over the next 12 months, ranging from a $17.00 high to a $10.00 low, as of Nov 19, 2026.
Is XRAY stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 12 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 7 rate it Neutral, and 2 rate it Sell or Strong Sell.
What are the highest and lowest price targets for XRAY?+
The Street-high target is $17.00 (UBS), and the Street-low is $10.00 (Leerink Partners). The average of all 12 active-firm targets is $13.33.
How many active Wall Street firms cover XRAY?+
12 active firms have a recognized rating on Dentsply Sirona Inc as of Nov 19, 2026, and 12 active firms carry a live 12-month price target.
Who is the most accurate analyst covering XRAY?+
Among analysts who currently cover XRAY, Erin Wright of Morgan Stanley has the strongest overall Quantellect track record (Rank #81). Their current call is Neutral.
What is Dentsply Sirona Inc's projected EPS for next quarter?+
The consensus estimate is $0.26 per share (range $0.23 – $0.30) across 11 analysts. Full-year EPS is projected at $1.32, rising to $1.22 the following year.
How much revenue is Dentsply Sirona Inc expected to report next quarter?+
Consensus revenue is $856.7M (range $832.0M – $877.3M). Full-year revenue is projected at $3.5B, growing to $3.5B next year.
Have analysts been upgrading or downgrading XRAY lately?+
As of Nov 19, 2026, 3 of 12 active firms rate XRAY a Buy (7 Neutral, 2 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their XRAY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.